CompanyGraph
Getinge AB
GETI.B · Nasdaq Stockholm · Sweden
Price data from its 0GZV listing on LSE
getinge.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $6.49B, above the global median of $1.15B
- PositionCurrent ratio is 1.31×, lower than 95% of its Medical Devices peers (median 3.83×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.93%Above 5Y avg (1.91%)
Annual Rate
SEK 4.75Paid annual
Payout Ratio
48.3%Sustainable
Payback Period
51.5 yr
Last Ex-Dividend
Apr 22, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
61.28BSEK6.49B · vs all stocks (USD)
Trailing P/E
24.48xvs Medical Devices peers
Revenue (TTM)
34.24BSEK3.63B · vs all stocks (USD)
Profit Margin
7.82%vs Medical Devices peers
Beta
0.8250xvs all stocks
52-Week Change
20.15%vs all stocks
Market Capitalization
61.28BSEK6.49B · vs all stocks (USD)
Enterprise Value
74.63BSEK7.90B · vs all stocks (USD)
Trailing P/E
24.48xvs Medical Devices peers
Forward P/E
21.99xvs Medical Devices peers
PEG Ratio
0.1353xvs Medical Devices peers
Price to Sales (TTM)
1.91xvs Medical Devices peers
Price to Book (MRQ)
2.12xvs Medical Devices peers
Enterprise to Revenue
2.18xvs Medical Devices peers
Enterprise to EBITDA
12.67xvs Medical Devices peers
Gross Margin
52.69%vs Medical Devices peers
Profit Margin
7.82%vs Medical Devices peers
Operating Margin
16.12%vs Medical Devices peers
Return on Assets (TTM)
5.25%vs Medical Devices peers
Return on Equity (TTM)
8.95%vs Medical Devices peers
Revenue (TTM)
34.24BSEK3.63B · vs all stocks (USD)
Revenue per Share (TTM)
125.70SEKUpdated Aug 20, 2026Quarterly Revenue Growth
1.70%vs Medical Devices peers
Gross Profit (TTM)
16.64BSEK1.76B · vs all stocks (USD)
EBITDA (TTM)
6.71BSEK710.80M · vs all stocks (USD)
Net Income (TTM)
2.68BSEK283.39M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
60.50%vs Medical Devices peers
Operating Cash Flow (TTM)
5.04BSEK533.31M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
2.85BSEK301.46M · vs all stocks (USD)
Trailing Annual Dividend Rate
4.75SEKUpdated Aug 20, 2026Trailing Annual Dividend Yield
1.93%vs all stocks
5-Year Average Dividend Yield
1.91%vs all stocks
Payout Ratio
48.32%vs Medical Devices peers
Minority Interest (Equity)
64.00MSEKFY2025 · Dec 31, 2025Revenue
34.97BSEKFY2025 · Dec 31, 2025Cost of Goods Sold
18.32BSEKFY2025 · Dec 31, 2025Gross Profit
16.65BSEKFY2025 · Dec 31, 2025Operating Income
4.46BSEK472.74M · vs all stocks (USD)
Pre-tax Income
3.15BSEKFY2025 · Dec 31, 2025Income Tax Expense
869.00MSEKFY2025 · Dec 31, 2025Net Income
2.28BSEKFY2025 · Dec 31, 2025EBIT
3.81BSEKFY2025 · Dec 31, 2025EBITDA (Income Statement)
6.45BSEKFY2025 · Dec 31, 2025Research & Development
1.45BSEKFY2025 · Dec 31, 2025Selling, General & Administrative
9.53BSEKFY2025 · Dec 31, 2025Other Operating Expenses
251.00MSEKFY2025 · Dec 31, 2025Non-operating Interest Income
73.00MSEKFY2025 · Dec 31, 2025Non-operating Interest Expense
660.00MSEKFY2025 · Dec 31, 2025Net Income from Continuing Operations
3.79BSEKFY2025 · Dec 31, 2025Minority Interests (P&L)
-17.00MSEKFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00SEKFY2025 · Dec 31, 2025Operating Cash Flow
2.94BSEKFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
3.40BSEKFY2025 · Dec 31, 2025Starting Profit (CF Statement)
3.79BSEKFY2025 · Dec 31, 2025Other Non-cash Items
336.00MSEKFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-218.00MSEKFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-969.00MSEKFY2025 · Dec 31, 2025Net Intangibles (CF)
-1.31BSEKFY2025 · Dec 31, 2025Net Acquisitions
-1.66BSEKFY2025 · Dec 31, 2025Other Investing Activity
17.00MSEKFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.65BSEKFY2025 · Dec 31, 2025Long-term Debt Issuance
3.26BSEKFY2025 · Dec 31, 2025Long-term Debt Payments
-2.26BSEKFY2025 · Dec 31, 2025Common Dividends Paid
-1.27BSEKFY2025 · Dec 31, 2025Other Financing Charges
3.00MSEKFY2025 · Dec 31, 2025Net Financing Cash Flow
-264.00MSEKFY2025 · Dec 31, 2025Shares Outstanding
272.37MSharesUpdated Aug 20, 2026Float Shares
178.53MSharesUpdated Aug 20, 2026% Held by Insiders
15.76%vs all stocks
% Held by Institutions
64.01%vs all stocks
Total Cash (MRQ)
2.05BSEK217.31M · vs all stocks (USD)
Total Cash per Share (MRQ)
7.53SEKUpdated Aug 20, 2026Total Debt (MRQ)
11.10BSEK1.18B · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3581xvs Medical Devices peers
Current Ratio (MRQ)
1.31xvs Medical Devices peers
Book Value per Share (MRQ)
113.61SEKUpdated Aug 20, 2026Total Assets
56.51BSEK5.98B · vs all stocks (USD)
Total Current Assets
17.23BSEKFY2025 · Dec 31, 2025Total Liabilities
27.01BSEKFY2025 · Dec 31, 2025Total Non-current Assets
39.28BSEKFY2025 · Dec 31, 2025Total Non-current Liabilities
13.97BSEKFY2025 · Dec 31, 2025Total Current Liabilities
13.04BSEKFY2025 · Dec 31, 2025Cash & Cash Equivalents
3.40BSEKFY2025 · Dec 31, 2025Accounts Receivable
5.78BSEKFY2025 · Dec 31, 2025Inventory
6.02BSEKFY2025 · Dec 31, 2025Accounts Payable
2.12BSEKFY2025 · Dec 31, 2025Short-term Debt
1.96BSEKFY2025 · Dec 31, 2025Other Current Liabilities
1.58BSEKFY2025 · Dec 31, 2025Long-term Debt
8.92BSEKFY2025 · Dec 31, 2025Other Non-current Liabilities
451.00MSEKFY2025 · Dec 31, 2025Common Stock (Book)
136.00MSEKFY2025 · Dec 31, 2025Retained Earnings
21.50BSEKFY2025 · Dec 31, 2025Total Shareholders' Equity
29.49BSEK3.12B · vs all stocks (USD)
52-Week Low
175.90SEKUpdated Aug 20, 202652-Week High
246.30SEKUpdated Aug 20, 202652-Week Change
20.15%vs all stocks
Beta
0.8250xvs all stocks
50-Day MA
215.70SEKUpdated Aug 20, 2026200-Day MA
204.97SEKUpdated Aug 20, 2026Avg 10-Day Volume
383.99KSharesUpdated Aug 20, 2026Avg 30-Day Volume
569.42KSharesUpdated Aug 20, 2026Diluted EPS (TTM)
9.83SEKUpdated Aug 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 1.31×, lower than 95% of its Medical Devices peers (median 3.83×)Significant
Current ratio: 1.31Industry median: 3.83Industry P5: 1.47Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.53Profit Margin: 0.08
Financial Health
Altman Z-Score 2.82: safe zoneNotable
Altman Z-Score: 2.82
High earnings qualityNotable
Earnings Quality Score: 0.60
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $6.49B, above the global median of $1.15BNotable
Market cap (USD): 6,489,886,024.485Global Median: 1,146,734,693.424
Revenue is $3.63B, above the global median of $520.53MNotable
Revenue (USD): 3,625,592,427.11Global Median: 520,528,949.311
Levered free cash flow is $301.46M, above the global median of $16.24MNotable
Levered free cash flow (USD): 301,457,590.042Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Ptc Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Erasca, Inc.
Tier 1ProductionApproval-Gated PipelineRule
H. Lundbeck A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
Glenmark Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xenon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sunshine Guojian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CG Oncology, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Scholar Rock Holding Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cogent Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen New Industries Biomedical Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
JCHX Mining Management Co., Ltd.
1 interpretationMulti-Year Revenue, Profit, And Income Growth
Colgate-Palmolive Company
1 interpretationMulti-Year Revenue, Profit, And Income Growth
Young & Co.'s Brewery Plc Class A
1 interpretationMulti-Year Revenue, Profit, And Income Growth